|
US7045313B1
(en)
|
1982-11-30 |
2006-05-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
|
|
US5168062A
(en)
|
1985-01-30 |
1992-12-01 |
University Of Iowa Research Foundation |
Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US5443964A
(en)
|
1987-08-10 |
1995-08-22 |
Duke University |
Poxvirus insertion/expression vector
|
|
US6410010B1
(en)
|
1992-10-13 |
2002-06-25 |
Board Of Regents, The University Of Texas System |
Recombinant P53 adenovirus compositions
|
|
EP0584266B1
(en)
|
1991-05-06 |
2003-09-03 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Recombinant virus expressing carcinoembryonic antigen and methods of use thereof
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
US5262522A
(en)
|
1991-11-22 |
1993-11-16 |
Immunex Corporation |
Receptor for oncostatin M and leukemia inhibitory factor
|
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
|
US5457035A
(en)
|
1993-07-23 |
1995-10-10 |
Immunex Corporation |
Cytokine which is a ligand for OX40
|
|
WO1996009380A1
(en)
|
1994-09-23 |
1996-03-28 |
The University Of British Columbia |
Method of enhancing expression of mhc class i molecules bearing endogenous peptides
|
|
DE69519521T2
(de)
|
1994-10-03 |
2001-06-28 |
The Government Of The United States Of America, As Represented By The Secretary National Institute Of Health |
Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus
|
|
US5998205A
(en)
|
1994-11-28 |
1999-12-07 |
Genetic Therapy, Inc. |
Vectors for tissue-specific replication
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
ATE299938T1
(de)
|
1997-05-02 |
2005-08-15 |
Genentech Inc |
Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
|
|
ATE375365T1
(de)
|
1998-04-02 |
2007-10-15 |
Genentech Inc |
Antikörper varianten und fragmente davon
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
GB2337755B
(en)
|
1998-05-29 |
2003-10-29 |
Secr Defence |
Virus vaccine
|
|
US6375952B1
(en)
|
1998-08-07 |
2002-04-23 |
University Of Washington |
Immunological herpes simplex virus antigens and methods for use thereof
|
|
US6682736B1
(en)
|
1998-12-23 |
2004-01-27 |
Abgenix, Inc. |
Human monoclonal antibodies to CTLA-4
|
|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
PL209392B1
(pl)
|
1999-01-15 |
2011-08-31 |
Genentech Inc |
Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
|
|
CA2379166C
(en)
|
1999-08-09 |
2013-03-26 |
Targeted Genetics Corporation |
Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs
|
|
PL354286A1
(en)
|
1999-08-23 |
2003-12-29 |
Dana-Farber Cancer Institutedana-Farber Cancer Institute |
Pd-1, a receptor for b7-4, and uses therefor
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
EP1212422B1
(en)
|
1999-08-24 |
2007-02-21 |
Medarex, Inc. |
Human ctla-4 antibodies and their uses
|
|
US7329728B1
(en)
|
1999-10-25 |
2008-02-12 |
The Scripps Research Institute |
Ligand activated transcriptional regulator proteins
|
|
US7011972B2
(en)
|
2000-07-18 |
2006-03-14 |
The Scripps Research Institute |
Fusion polypeptide comprising two ligand binding domains
|
|
AU2002368044A1
(en)
*
|
2001-06-22 |
2004-04-19 |
Maxygen, Inc. |
Co-stimulatory molecules
|
|
DE60235041D1
(de)
|
2001-11-30 |
2010-02-25 |
Us Gov Health & Human Serv |
Und ihre verwendung
|
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
|
NZ536420A
(en)
|
2002-04-12 |
2008-04-30 |
Medarex Inc |
Methods of treatment using CTLA-4 antibodies
|
|
IL149820A0
(en)
|
2002-05-23 |
2002-11-10 |
Curetech Ltd |
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
|
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
TWI335821B
(en)
|
2002-12-16 |
2011-01-11 |
Genentech Inc |
Immunoglobulin variants and uses thereof
|
|
CN101899114A
(zh)
|
2002-12-23 |
2010-12-01 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
US7158164B2
(en)
|
2003-08-29 |
2007-01-02 |
Fuji Photo Film Co., Ltd. |
Thermal development method and apparatus
|
|
PT1718677E
(pt)
|
2003-12-19 |
2012-07-18 |
Genentech Inc |
Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
|
|
PT1737891E
(pt)
|
2004-04-13 |
2013-04-16 |
Hoffmann La Roche |
Anticorpos anti p-selectina
|
|
EP2471813B1
(en)
|
2004-07-15 |
2014-12-31 |
Xencor, Inc. |
Optimized Fc variants
|
|
US20070166281A1
(en)
|
2004-08-21 |
2007-07-19 |
Kosak Kenneth M |
Chloroquine coupled antibodies and other proteins with methods for their synthesis
|
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ｏｘ４０ｌ抗體
|
|
US20090208924A1
(en)
|
2004-12-01 |
2009-08-20 |
Bayer Schering Pharma Aktiengesellschaft |
Generation of Replication Competent Viruses for Therapeutic Use
|
|
DK2439273T3
(da)
|
2005-05-09 |
2019-06-03 |
Ono Pharmaceutical Co |
Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
|
|
PT1907424E
(pt)
|
2005-07-01 |
2015-10-09 |
Squibb & Sons Llc |
Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
|
|
EP1960525B1
(en)
|
2005-09-09 |
2013-04-24 |
Zymogenetics, Inc. |
Method for preparing trimeric proteins
|
|
WO2008092117A2
(en)
|
2007-01-25 |
2008-07-31 |
Xencor, Inc. |
Immunoglobulins with modifications in the fcr binding region
|
|
BR122017025062B8
(pt)
|
2007-06-18 |
2021-07-27 |
Merck Sharp & Dohme |
anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
|
|
KR20100052545A
(ko)
*
|
2007-08-28 |
2010-05-19 |
바이오겐 아이덱 엠에이 인코포레이티드 |
Ｉｇｆ―１ｒ의 다중 에피토프에 결합하는 조성물
|
|
PL2222861T3
(pl)
|
2007-12-11 |
2018-04-30 |
The University Of North Carolina At Chapel Hill |
Wektory retrowirusowe ze zmodyfikowanym odcinkiem polipurynowym
|
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
|
AU2009288730B2
(en)
|
2008-08-25 |
2013-06-20 |
Amplimmune, Inc. |
Compositions of PD-1 antagonists and methods of use
|
|
JP2012500855A
(ja)
|
2008-08-25 |
2012-01-12 |
アンプリミューン、インコーポレーテッド |
Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
|
|
JP5551702B2
(ja)
|
2008-09-16 |
2014-07-16 |
ヒストロックス，インコーポレイテッド． |
バイオマーカー発現の再現性のある定量
|
|
WO2011066342A2
(en)
|
2009-11-24 |
2011-06-03 |
Amplimmune, Inc. |
Simultaneous inhibition of pd-l1/pd-l2
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
KR20140004174A
(ko)
|
2011-01-18 |
2014-01-10 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
암 치료를 위한 조성물 및 방법
|
|
EP2686345B1
(en)
|
2011-03-16 |
2018-04-25 |
Amgen Inc. |
Fc variants
|
|
EA027236B1
(ru)
|
2011-04-08 |
2017-07-31 |
Иммьюн Дизайн Корп. |
Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
|
|
JP6072771B2
(ja)
|
2011-04-20 |
2017-02-01 |
メディミューン，エルエルシー |
Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
|
|
CN103946952A
(zh)
|
2011-09-16 |
2014-07-23 |
宾夕法尼亚大学董事会 |
用于治疗癌症的rna改造的t细胞
|
|
US8956619B2
(en)
*
|
2011-10-25 |
2015-02-17 |
University Of Maryland, Baltimore County |
Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
|
|
JP6355563B2
(ja)
|
2012-02-27 |
2018-07-11 |
アムニクス オペレーティング インコーポレイテッド |
Ｘｔｅｎ共役組成物およびそれを製造する方法
|
|
WO2014055657A1
(en)
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
|
EP2912063A1
(en)
|
2012-10-23 |
2015-09-02 |
Bristol-Myers Squibb Company |
Combination of anti-kir and anti-ctla-4 antibodies to treat cancer
|
|
JP2016514676A
(ja)
*
|
2013-03-15 |
2016-05-23 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ |
四価二重特異性抗体
|
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
|
JP2016515120A
(ja)
|
2013-03-15 |
2016-05-26 |
バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． |
抗アルファｖベータ５抗体を用いた急性腎損傷の治療及び予防
|
|
CN104250302B
(zh)
|
2013-06-26 |
2017-11-14 |
上海君实生物医药科技股份有限公司 |
抗pd‑1抗体及其应用
|
|
CN112552401B
(zh)
|
2013-09-13 |
2023-08-25 |
广州百济神州生物制药有限公司 |
抗pd1抗体及其作为治疗剂与诊断剂的用途
|
|
RU2727639C2
(ru)
|
2014-01-15 |
2020-07-22 |
Ф.Хоффманн-Ля Рош Аг |
Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а
|
|
CA2940115C
(en)
|
2014-02-24 |
2023-03-14 |
Ventana Medical Systems, Inc. |
Methods, kits, and systems for scoring the immune response to cancer by simultaneous detection of cd3, cd8, cd20 and foxp3
|
|
JP6652557B2
(ja)
|
2014-05-30 |
2020-02-26 |
ヴェンタナ メディカル システムズ， インク． |
Ｐｄ−ｌ１について染色された腫瘍組織の改善されたスコア化のための多重アッセイ
|
|
RU2715038C2
(ru)
|
2014-07-11 |
2020-02-21 |
Дженентек, Инк. |
Антитела анти-pd-l1 и способы их диагностического применения
|
|
KR20170032373A
(ko)
|
2014-07-15 |
2017-03-22 |
이뮨 디자인 코포레이션 |
Tlr4 작용제 보조제 및 렌티바이러스 벡터를 이용한 프라임-부스트 요법
|
|
CA3138083A1
(en)
*
|
2014-12-22 |
2016-06-30 |
Systimmune, Inc. |
Bispecific tetravalent antibodies and methods of making and using thereof
|
|
US10273281B2
(en)
*
|
2015-11-02 |
2019-04-30 |
Five Prime Therapeutics, Inc. |
CD80 extracellular domain polypeptides and their use in cancer treatment
|
|
WO2017085307A1
(en)
|
2015-11-22 |
2017-05-26 |
Ventana Medical Systems, Inc. |
Methods of identifying immune cells in pd-l1 positive tumor tissue
|
|
US10613092B2
(en)
|
2016-04-01 |
2020-04-07 |
Agilent Technologies, Inc. |
Scoring methods for anti-PD therapy eligibility and compositions for performing same
|
|
SG11201808626WA
(en)
|
2016-04-07 |
2018-10-30 |
Chemocentryx Inc |
Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
|
|
WO2017181152A2
(en)
*
|
2016-04-15 |
2017-10-19 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
|
WO2018075978A1
(en)
*
|
2016-10-20 |
2018-04-26 |
Alpine Immune Sciences, Inc. |
Secretable variant immunomodulatory proteins and engineered cell therapy
|
|
DK3541841T3
(da)
|
2016-11-18 |
2024-10-21 |
Servier Lab |
Anti-PD-1-antistoffer og sammensætninger
|
|
MA47604A
(fr)
|
2017-02-21 |
2020-01-01 |
Regeneron Pharma |
Anticorps anti-pd-1 pour le traitement du cancer du poumon
|
|
SG11201907769XA
(en)
*
|
2017-03-16 |
2019-09-27 |
Alpine Immune Sciences Inc |
Cd80 variant immunomodulatory proteins and uses thereof
|